French Infrastructure Stock News

Sanofi (ENXTPA:SAN) shares have quietly bounced about 2% over the past week, even though they are still down for the year, drawing attention from investors looking for more resilient pharma exposure. See our latest analysis for Sanofi. That recent 7 day share price return of 2.21 percent only slightly offsets a year to date share price decline of 12.66 percent. This suggests sentiment is stabilising rather than surging, despite steady earnings growth and pipeline progress. If Sanofi has you...

BASSAC Société anonyme's ( EPA:BASS ) price-to-earnings (or "P/E") ratio of 8.7x might make it look like a buy right...

Kering (ENXTPA:KER) has quietly climbed this year, and with the share price hovering around €303 after a recent pullback, investors are starting to reassess whether the luxury group’s recovery has more room to run. See our latest analysis for Kering. The recent pullback sits against a strong backdrop, with a roughly 28 percent year to date share price return. This suggests sentiment toward Kering’s turnaround is improving even as the three and five year total shareholder returns remain deeply...

Nexans S.A. ( EPA:NEX ), might not be a large cap stock, but it received a lot of attention from a substantial price...

Key Insights Given the large stake in the stock by institutions, Alten's stock price might be vulnerable to their...

Enogia SAS ( EPA:ALENO ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...

Groupe LDLC société anonyme ( EPA:ALLDL ) shares have continued their recent momentum with a 29% gain in the last month...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Veolia Environnement SA ( EPA:VIE ) saw its share price hover around a small range of €28.40 to €29.97 over the last...

Those holding EKINOPS S.A. ( EPA:EKI ) shares would be relieved that the share price has rebounded 31% in the last...

Shareholders might have noticed that EXEL Industries SA ( EPA:EXE ) filed its annual result this time last week. The...

If you are wondering whether Sanofi is quietly turning into a bargain while everyone is focused on flashier names, this deep dive will help you assess whether the current price reflects its long term potential. Despite a solid 5 year gain of 28.1%, the stock is down 12.7% year to date and 4.6% over the last month, suggesting that sentiment has cooled even as the long term story remains intact. Recently, markets have been reacting to Sanofi's strategic shifts in its pharmaceutical pipeline...

If you are wondering whether LVMH Moët Hennessy Louis Vuitton Société Européenne is still a quality luxury name at a fair price, you are not alone. That is exactly what we are going to unpack here. The share price has been relatively steady but slightly positive, up around 1.2% over the last week and 3.6% over the past month, while sitting roughly flat year to date and modestly higher over 1 year. This hints at cautious optimism rather than a runaway rally. Recent headlines have focused on...

Wondering if Publicis Groupe is quietly turning into a value opportunity, or if the market has already priced in the upside? The stock has edged up about 1.5% over the last week and 5.5% over the past month, even though it is still down roughly 13.9% year to date and 10.2% over the last year after a very strong 3 and 5 year run. Recent headlines have focused on Publicis tightening its focus on high margin data and tech led services and securing new global client mandates, reinforcing its...

74Software (74SW) has quietly put up a strong run this year, with the stock gaining nearly 50% year to date, supported by steady revenue expansion and faster growing profits. See our latest analysis for 74Software. The recent rally has been driven more by a reappraisal of 74Software’s growth prospects than any single headline, with a 12.82 percent 1 month share price return adding to an already impressive 49.43 percent year to date share price gain and strong multi year total shareholder...

Wondering if Getlink is quietly becoming good value, or if the recent price leaves little upside on the table? Let us unpack what the market is really pricing into this cross Channel operator. The share price has edged up 1.4% over the last week and 1.0% over the last month, yet it is still roughly flat year to date at -0.6%, with a steadier 4.9% gain over the past year. Recent headlines have focused on traffic recovery through the Channel Tunnel and ongoing infrastructure investment plans...

Wondering if TotalEnergies is still a smart buy at today’s price, or if most of the upside has already been captured? Let us break down what the current share price is really implying about its long term value. The stock has been relatively steady in the short term, up 0.4% over the last week and 0.7% over the past month, but it has quietly delivered a solid 3.9% year to date and 14.3% over the last year, on top of a 110.6% gain across five years. Recent share price resilience has come as...

With the business potentially at an important milestone, we thought we'd take a closer look at Amoéba S.A.'s...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Median Technologies SA ( EPA:ALMDT ) shareholders would be excited to see that the share price has had a great month...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

When close to half the companies in France have price-to-earnings ratios (or "P/E's") above 17x, you may consider NSC...

Safran (ENXTPA:SAF) has quietly added to its strong run this year, with the stock edging higher over the past week and sitting on roughly 43% gains year to date. See our latest analysis for Safran. That latest move takes Safran’s share price to about €306.3, capping a strong year in which the share price return and longer term total shareholder returns suggest momentum is still building rather than fading. If Safran’s run has you rethinking your aerospace exposure, this could be a good moment...

DBV Technologies recently reported that its Phase 3 VITESSE trial of the VIASKIN Peanut patch for peanut‑allergic children aged 4–7 met its primary endpoint with statistically significant efficacy and a favorable safety profile, and the company now plans to submit a Biologics License Application to the US FDA in the first half of 2026. An important angle for investors is that this late-stage success follows earlier regulatory setbacks, suggesting the redesigned patch and trial design may...